Note: Click on the chart and scroll for continuous zoom
- Not included: trials with a status of withdrawn, terminated, unknown, or started prior to 2020.
- Trial date range starts with the primary study completion date ends with the study completion published on clinicaltrials.gov.
- For the timeline's readability and usability reasons, the smallest increment between the primary and study completion date is 10 days. There are a few cases where those dates are identical on clinicaltrials.gov.
- IBRX completes and withdraws studies without announcement, so there's no way to know if/when results are forthcoming. They also occasionally release preliminary data prior to study completion.
- Reporting requirement for National Cancer Institute-sponsored studies: Within 12 months of the earlier of estimated/actual primary completion date.
- Drugs may have multiple names. For example: Anktiva = N-803 = Alt-803 = Inbakicept
Copyright 2026, Ben Rogers